March 04 - 06, 2013
Miami, Florida

Pharma Companies

The Pharma Company's New Competitive Challenge: License and Acquire the Next Blockbuster Drugs


Click Here to Listen to the Free Podcast

Big pharma are constantly and actively looking for partners who are innovating with new drug discovery and development, but how do these partnerships actually happen? How does a big corporation like GlaxoSmithKline hone in on the right biotech companies to advance its own organization’s goals?

One way is to segment the company into smaller groups, like the Centre of Excellence for External Drug Discovery (CEEDD) at GSK, where David Donabedian is the VP of Strategic Alliances. The CEEDD was formed out of the realization that R&D is best done in small groups and it’s working for the organization at large.

Hear how David has led the CEEDD group to form recent partnerships with companies like OncoMed and Prosensa Therapeutics, among others, in this exclusive podcast.

Click on the image at left to hear the podcast.



The latest information from the U.S. Food and Drug Administration shows that over ninety drug products including vaccines based on biotechnology have already been approved. The US spent over nine billion dollars on research and development of biotechnology. A growing industry that blends biotech development and investment, while funding the independent research needed for pharmaceutical products on the horizon. Pharma companies both largh and small are partnering with the biotech firms and through ventures, and acquisitions finding new ways to fuel the drug development field. The horizon is just beginning to open.

With biotech's best years ahead, especially in the avenue of pharma companies, there are new adventures around every corner. There are many biotechnology drugs currently in trials and thousands more in clinical research and development. Years ago it was believed that these biotech's that were just starting would grow into their own pharmaceutical companies, but now that belief is shifting. Instead of the traditional venture capital supporting these pharma companies switched gears and biotech companies began to specialize in other markets, focusing on gene therapy, drug delivery and other more directed areas. The pharma company started working with the biotech firms to provide funds needed for the research and development. This opened the door for the expansion and development we are seeing today. The competition is also expanding and as with all markets there will be some that survive and some that disappear. Not all investments will be prosperous, and not all the drugs will be break throughs for progress.

So as each pharma company makes larger investments with the bio tech firms, and very early in the process, the risk they undertake is large. Is the risk worth it? Well as you look at the industry, look forward to the evolution that is coming. It is unknown if the risk will pay off, but it is the leading edge, the wave of the future, the benefit that could save many lives, or prevent the next plague. Risk is always there for new products, new drugs and new research. The answers are all unknown, but so are the benefits we have to gain.

Theme2 Master Page Theme2 PageName:smartdynamicform.aspx EventInfo Id = 164416 Content Id = 170560 Content Title = pharma-companies